In this Editorial Article, Dr. Peter Wolff -Implementation Scientist, AGC Biologics -describes the potential of BsAbs as an exciting immuno-oncology therapeutic and the role of the CD3 receptor in their mode of action.
Dr. Wolff also explores how reliable and robust cell-based assays and analytical techniques are integral in the assistance of bringing these new modality drugs to market.